Navigation Links
Covance Board Authorizes $250 Million Stock Buyback
Date:9/28/2010

PRINCETON, N.J., Sept. 28 /PRNewswire-FirstCall/ -- Covance Inc. (NYSE: CVD) said today that its Board of Directors has authorized the repurchase of up to $250 million of its outstanding common stock. This authorization is in addition to the approximately 800,000 shares remaining under the repurchase authorization announced in 2007 and currently represents nearly ten percent of the Company's common stock. Any purchases under this buyback would be dependent upon business and market conditions and other factors. The stock purchases may be made from time to time and may be made through a variety of methods including open market purchases, privately negotiated transactions, block trades, and 10b5-1 plans.

"This action reflects the confidence of the Board and management in the fundamental strengths and future outlook of Covance," said Joe Herring, Chairman and Chief Executive Officer of Covance.

About Covance

Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1.8 billion, global operations in more than 30 countries, and more than 10,000 employees worldwide.  Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on manag
'/>"/>

SOURCE Covance Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
2. Covance Receives Highest Level of Phase I Accreditation
3. Covance Inc. Invites You to Join the Webcast of Its Fourth Quarter 2009 Financial Results Conference Call
4. Covance to Present at the 28th Annual J.P. Morgan Healthcare Conference
5. Rules-Based Medicine Forms Biomarker Alliance With Covance Inc.
6. Covance Enters Into a Biomarker Alliance With Rules-Based Medicine, Inc.
7. Covance to Present at Piper Jaffray 21st Annual Health Care Conference
8. Covance To Present At The 20th Annual Global Healthcare Services Conference
9. Covance To Present at the Deutsche Bank 35th Annual Health Care Conference
10. Covance to Present at Goldman Sachs 31st Annual Global Healthcare Conference
11. Covance to Present at William Blair & Companys 30th Annual Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , N.Y. and MEXICO CITY , ... today announced that PLM, a Latin American healthcare sciences ... to deliver medical information on conditions such as cancer ... can now access the most up-to-date information to deliver ... medical professionals is growing rapidly, with many relying on ...
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and General ... and Packaging (EMIP) Division. "I am pleased ... management and business development experience, especially in the medical ... contributions to the continued growth and success of our ...
(Date:7/25/2014)... NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR ... JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF ... ABBV ) today announced financial results for the ... was another very strong quarter for AbbVie, as we delivered ... announced plans to merge with Shire, a strategic action that ...
Breaking Medicine Technology:Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 2Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 3Healthcare Sciences Publisher PLM and IBM Speed Access to Medical Information to Deliver Better Patient Care with Mobile 4AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2AbbVie Reports Second-Quarter 2014 Financial Results 2AbbVie Reports Second-Quarter 2014 Financial Results 3AbbVie Reports Second-Quarter 2014 Financial Results 4AbbVie Reports Second-Quarter 2014 Financial Results 5AbbVie Reports Second-Quarter 2014 Financial Results 6AbbVie Reports Second-Quarter 2014 Financial Results 7AbbVie Reports Second-Quarter 2014 Financial Results 8AbbVie Reports Second-Quarter 2014 Financial Results 9AbbVie Reports Second-Quarter 2014 Financial Results 10AbbVie Reports Second-Quarter 2014 Financial Results 11AbbVie Reports Second-Quarter 2014 Financial Results 12AbbVie Reports Second-Quarter 2014 Financial Results 13AbbVie Reports Second-Quarter 2014 Financial Results 14AbbVie Reports Second-Quarter 2014 Financial Results 15AbbVie Reports Second-Quarter 2014 Financial Results 16AbbVie Reports Second-Quarter 2014 Financial Results 17AbbVie Reports Second-Quarter 2014 Financial Results 18AbbVie Reports Second-Quarter 2014 Financial Results 19AbbVie Reports Second-Quarter 2014 Financial Results 20AbbVie Reports Second-Quarter 2014 Financial Results 21AbbVie Reports Second-Quarter 2014 Financial Results 22AbbVie Reports Second-Quarter 2014 Financial Results 23AbbVie Reports Second-Quarter 2014 Financial Results 24AbbVie Reports Second-Quarter 2014 Financial Results 25AbbVie Reports Second-Quarter 2014 Financial Results 26AbbVie Reports Second-Quarter 2014 Financial Results 27AbbVie Reports Second-Quarter 2014 Financial Results 28AbbVie Reports Second-Quarter 2014 Financial Results 29AbbVie Reports Second-Quarter 2014 Financial Results 30AbbVie Reports Second-Quarter 2014 Financial Results 31AbbVie Reports Second-Quarter 2014 Financial Results 32
... SEATTLE, March 25 Cell Therapeutics, Inc.,(CTI) (Nasdaq: ... complete in,the phase III EXTEND (PIX301) clinical trial of ... non-Hodgkin,s lymphoma (NHL).,An analysis of the data is expected ... with the U.S. Food and Drug Administration (FDA) the ...
... Patients to ... Higher Rates of BARACLUDE Resistance -, PRINCETON, N.J., ... a continued low incidence of,resistance in nucleoside-naive patients through ... patients analyzed, no additional,patient developed resistance in the fifth ...
Cached Medicine Technology:Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 2Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 3Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 2BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 3BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 4BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 5BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients 6
(Date:7/26/2014)... The North America Cyber Security report defines and ... with analysis and forecast of revenue. This market is ... to $33.24 billion by 2019, at a CAGR of ... TOC of the North America Cyber Security Market report ... It also provides a glimpse of the segmentation in ...
(Date:7/26/2014)... SATURDAY, July 26, 2014 (HealthDay News) -- Pools can ... can make themselves sick if they swallow too much ... excitement, it,s common for little ones to get water ... drink from a pool, despite warnings from their parents. ... is harmless, it,s important for parents to realize that ...
(Date:7/26/2014)... July 26, 2014 According ... updated by Vkool.com, this is a comprehensive ... methods for treating all types of ...     Tinnitus due to Ménière's disease ...     Nerve pathway tinnitus ,     Inner, ...
(Date:7/26/2014)... 2014 The U.S. Food & Drug Administration ... a new medication guide for AndroGel to include blood clots ... taking the topical low testosterone medication, notes Wright & Schulte ... makers of the low testosterone theapy drug, has also updated ... or redness as signs of a blood clot in the ...
(Date:7/26/2014)... According to the "Get Rid Tattoo ... a comprehensive guide that provides readers with safe and ... book also teaches them how to fade dark colored ... their own home for drastic results. , Vkool ... book includes step-by-step tutorials and product recommendations for treating ...
Breaking Medicine News(10 mins):Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America Cyber Security Market is Expected to Reach $33 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Don't Let Kids Drink Pool Water 2Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 2Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 3Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 4Health News:FDA Updates AndroGel Risks to Include Blood Clots In Legs and Lungs as Testosterone Treatment Lawsuits Move Forward 5Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3
... effect , MONDAY, Oct. 5 (HealthDay News) -- Although ... this isn,t reason enough for most people to stop eating ... blood pressure due to methylmercury will never outweigh the benefits ... in the department of social and preventive medicine at Laval ...
... desired antibodies in some, but effects were fleeting, scientists say ... help cocaine addicts beat their habit is showing some effect ... more than one-third of participants in a new study developed ... this group, cocaine use did go down. But the effects ...
... New Delhi, Singapore and Washington DC (October 5, 2009) SAGE ... by Dr. Prem Reddy, founder and previous Editor-in-Chief of the ... field of cancer research is entering a new and exciting ... modern genetics are beginning to provide new clues into how ...
... Fewer secondary schools in the United States are selling ... according to a survey from the Centers for Disease Control ... in states that have adopted strong school nutrition standards and ... , The report, "Availability of Less Nutritious Snack Foods ...
... Mass., Oct. 5 Hologic, Inc. (Hologic or the ... and supplier of premium diagnostics, medical imaging systems and ... women, today announced plans to release its fourth quarter ... 2009 after market close. In conjunction with the release, ...
... Fred Hutchinson Cancer Research Center have been awarded 60 ... Recovery & Reinvestment Act of 2009. The totals reflect ... the National Institutes of Health. , The individual projects ... benefit every level of researcher at the Hutchinson Center, ...
Cached Medicine News:Health News:Mercury in Fish Linked to High Blood Pressure 2Health News:Mercury in Fish Linked to High Blood Pressure 3Health News:Cocaine Addiction Vaccine Shows Some Success 2Health News:Cocaine Addiction Vaccine Shows Some Success 3Health News:SAGE launches Genes & Cancer 2Health News:Fewer U.S. Schools Selling Less Nutritious Food and Beverages 2Health News:Hologic to Release Fourth Quarter and Fiscal 2009 Operating Results on Monday, November 9, 2009 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 2Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 3Health News:Federal Stimulus Funding Channels More Than $40 Million to Fred Hutchinson Cancer Research Center 4
... VICTOR2 V ... fluorescence polarization, luminescence, ... and absorbance. A ... LANCE assay. All ...
This is the modular VICTOR2 multilabel counter with the TR-fluorometry, stacker and robot loading options.The addition of a xenon flash lamp brings the time-resolved fluorescence counting mode to th...
This is the modular manually operated VICTOR2 multilabel counter, with the addition of a xenon flash lamp for time-resolved fluorescence counting. Along with this option comes flash absorbance and du...
... readers available today operate with either one, ... speed) or use an imaging process to ... sensitivity and the individual signals can overlap). ... miniature lens array containing 96 parallel micro-objectives. ...
Medicine Products: